1 not yet recruiting, 1 unknown. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Yongsheng Wang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy letrozole - Locally Advanced Breast Cancer, Hormone Receptor Positiveļ¼HER2-negative Breast Cancer | Phase 4 | Unknown | Yongsheng Wang | 100 | 2023-03-01 | 2023-04-12 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
Letrozole (1) · aumolertinib (1)
China (1)